Inventor

David M. Goldenberg

Inventor

Mendham, NJ, US

Overview

1994–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 370 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes25%

C07KPeptides23%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%

B82YSpecific uses or applications of nanostructures9%

G01NInvestigating or analysing materials by determining their chemical or physical properties4%

C12NMicroorganisms or enzymes3%

A61NElectrotherapy3%

Y02ATechnologies for adaptation to climate change3%

C07DHeterocyclic compounds2%

A61BDiagnosis2%

PatentTitleYear

RE048751Immunoconjugates with an intracellularly-cleavable linkage2021 11,116,846Antibody-drug conjugates and uses thereof2021 11,077,201Immunoconjugates with an intracellularly-cleavable linkage2021 11,052,081Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)2021 11,052,156Antibody-drug conjugates and uses thereof2021 10,849,986Antibody-drug conjugates and uses thereof2020 10,799,597Subcutaneous administration of antibody-drug conjugates for cancer therapy2020 10,751,420Antibody-SN-38 immunoconjugates with a CL2A linker2020 10,744,129Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-22020 10,709,701Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers2020 10,682,347Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity2020 10,669,338Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-12020 10,662,252Disease therapy by inducing immune response to Trop-2 expressing cells2020 10,653,793Antibody-drug conjugates and uses thereof2020 10,561,738Immunoconjugates with an intracellularly-cleavable linkage2020 10,436,788Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells2019 10,413,539Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)2019 10,385,139Murine, chimeric, humanized or human anti-TNF-alpha antibodies2019 10,377,829Isolated nucleic acid encoding an anti-IGF-1R antibody2019 10,322,176Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus2019 10,322,193Immunoconjugates with an intracellularly-cleavable linkage2019 10,308,688T-cell redirecting bispecific antibodies for treatment of disease2019 10,266,605Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors2019 10,265,414Immunoconjugates with an intracellularly-cleavable linkage2019 10,245,321Combination therapy for inducing immune response to disease2019 10,239,938T-cell redirecting bispecific antibodies for treatment of disease2019 10,206,918Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers2019 10,195,175Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors2019 10,183,992T-cell redirecting bispecific antibodies for treatment of disease2019 10,179,171RS7 antibodies2019 10,174,114Humanized anti-HLA-DR antibodies2019 10,160,801Nucleic acids encoding chimeric and humanized anti-histone antibodies2018 10,143,756Antibody-SN-38 immunoconjugates with a CL2A linker2018 10,137,196Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity2018 10,131,712Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors2018 10,130,626Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity2018 10,130,718Antibody-drug conjugates and uses thereof2018 10,111,954Combination therapy for inducing immune response to disease2018 10,064,957Immunoconjugates with an intracellularly-cleavable linkage2018 10,058,621Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers2018 10,040,848Chimeric and humanized anti-histone antibodies2018 10,034,950Antibody-SN-38 immunoconjugates with a CL2A linker2018 10,022,427Interferon lambda-antibody complexes2018 9,999,668RS7 antibodies2018 9,993,547T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines2018 9,963,507Therapeutic use of anti-CD22 antibodies for inducing trogocytosis2018 9,963,516Stable compositions of high-concentration allotype-selected antibodies for small-volume administration2018 9,944,703Humanized anti-CD22 antibody2018 9,931,417Antibody-SN-38 immunoconjugates with a CL2A linker2018 9,932,413Murine, chimeric, humanized or human anti-IL-6 antibodies2018 9,931,413Tetrameric cytokines with improved biological activity2018 9,920,116'Methods for treating ischemic stroke using chimeric and humanized anti-histone antibodies'2018 9,879,088'Disease therapy by inducing immune response to Trop-2 expressing cells'2018 9,872,920PEGylation by the dock and lock (DNL) technique2018 9,862,770'Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors'2018 9,855,344'Antibody-SN-38 immunoconjugates with a CL2A linker'2018 9,849,176RS7 antibodies2017 9,839,689'Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy'2017 9,833,511RS7 antibodies2017 9,809,646'Methods for treating thrombosis using chimeric and humanized anti-histone antibodies'2017 9,797,907'Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells'2017 9,770,517'Anti-Trop-2 antibody-drug conjugates and uses thereof'2017 9,757,458'Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells'2017 9,751,948'Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)'2017 9,745,380'RS7 antibodies'2017 9,745,374'Fusion proteins containing recombinant cytotoxic RNAses'2017 9,737,617'Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2017 9,707,300'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'2017 9,707,302'Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer'2017 9,700,634'Immunoconjugates with an intracellularly-cleavable linkage'2017 9,701,748'Humanized anti-CD22 antibody'2017 9,694,088'Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer'2017 9,687,547'T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines'2017 9,682,143'Combination therapy for inducing immune response to disease'2017 9,683,050'Stable compositions of high-concentration allotype-selected antibodies for small-volume administration'2017 9,675,706'Immunoconjugates with an intracellularly-cleavable linkage'2017 9,670,286'Disease therapy by inducing immune response to Trop-2 expressing cells'2017 9,663,576'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2017 9,657,093'Methods for treating sepsis using chimeric and humanized anti-histone antibodies'2017 9,629,926'Antibody-SN-38 immunoconjugates with a CL2A linker'2017 9,623,115'Dock-and-Lock (DNL) Complexes for Disease Therapy'2017 9,617,531'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock'2017 9,605,071'Anti-CD19 antibodies'2017 9,599,619'Anti-pancreatic cancer antibodies'2017 9,550,838'Dock-and-lock (DNL) complexes for therapeutic and diagnostic use'2017 9,540,618'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2017 9,540,435'Stably tethered structures of defined compositions with multiple functions or binding specificities'2017 9,522,959'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2016 9,518,115'Humanized anti-CD22 antibody'2016 9,513,293'Detection of early-stage pancreatic adenocarcinoma'2016 9,499,631'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2016 9,498,542'Tetrameric cytokines with improved biological activity'2016 9,493,573'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2016 9,493,574'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2016 9,492,561'Dock-and-Lock (DNL) Complexes for delivery of interference RNA'2016 9,492,566'Antibody-drug conjugates and uses thereof'2016 9,486,536'Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer'2016 9,481,878'Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity'2016 9,481,732'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2016 9,480,756'Immunoconjugates with an intracellularly-cleavable linkage'2016 9,475,884'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2016 9,475,883'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2016 9,468,689'Ultrafiltration concentration of allotype selected antibodies for small-volume administration'2016 9,457,072'Dock-and-lock (DNL) vaccines for cancer therapy'2016 9,457,100'PEGylation by the dock and lock (DNL) technique'2016 9,458,242'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2016 9,452,228'Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)'2016 9,446,123'Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy'2016 9,441,043'Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)'2016 9,416,197'Bispecific antibodies that neutralize both TNF-Î± and IL-6: novel therapeutic agent for autoimmune disease'2016 9,382,329'Disease therapy by inducing immune response to Trop-2 expressing cells'2016 9,375,489'Antibody-SN-38 immunoconjugates with a CL2A linker'2016 9,371,393'Class I anti-CEA antibodies and uses thereof'2016 9,359,443'Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases'2016 9,352,036'Delivery system for cytotoxic drugs by bispecific antibody pretargeting'2016 9,345,783'Immunoconjugates with an intracellularly-cleavable linkage'2016 9,315,567'T-cell redirecting bispecific antibodies for treatment of disease'2016 9,283,286'Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer'2016 9,278,129'Methods of treating rapidly progressive glomerulonephritis using chimeric and humanized anti-histone H4 antibodies'2016 9,272,029'Interferon lambada-antibody complexes'2016 9,272,057'Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy'2016 9,248,184'Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy'2016 9,238,084'Anti-mucin antibodies for early detection and treatment of pancreatic cancer'2016 9,238,081'Detection of early-stage pancreatic adenocarcinoma'2016 9,233,172'Immunoconjugates with an intracellularly-cleavable linkage'2016 9,226,973'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2016 9,198,978'Immunoconjugates with an intracellularly-cleavable linkage'2015 9,192,664'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2015 9,187,561'Humanized anti-HLA-DR antibodies'2015 9,184,781'Humanized antibodies and methods of humanizing antibodies'2015 9,180,205'Stable compositions of high-concentration allotype-selected antibodies for small-volume administration'2015 9,169,470'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2015 9,139,649'Humanized anti-CD22 antibody'2015 9,138,485'Immunoconjugates with an intracellularly-cleavable linkage'2015 9,139,657'Class I anti-CEA antibodies and uses thereof'2015 9,115,172'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2015 9,112,730'Centralized method for certifying credentials'2015 9,107,962'Anthracycline-antibody conjugates for cancer therapy'2015 9,107,960'Antibody-SN-38 immunoconjugates with a CL2A linker'2015 9,102,735'Immunoconjugates with an intracellularly-cleavable linkage'2015 9,095,628'Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer'2015 9,089,618'Anti-mucin antibodies for early detection and treatment of pancreatic cancer'2015 9,056,917'Anti-CD19 antibodies'2015 9,028,833'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'2015 9,028,800'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2015 9,005,613'Anti-mucin antibodies for early detection and treatment of pancreatic cancer'2015 8,999,344'Immunoconjugates with an intracellularly-cleavable linkage'2015 8,992,931'Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy'2015 8,992,917'Humanized L243 antibodies'2015 8,986,699'Anti-CD74 immunoconjugates and methods of use'2015 8,987,421'Chimeric and humanized anti-histone antibodies'2015 8,974,784'Anti-pancreatic cancer antibodies'2015 8,945,554'Class I anti-CEA antibodies and uses thereof'2015 8,932,593'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2015 8,906,377'Stably tethered structures of defined compositions with multiple functions or binding specificities'2014 8,906,378'Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases'2014 8,895,013'Anthracycline-antibody conjugates for cancer therapy'2014 8,889,100'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2014 8,889,835'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'2014 8,889,410'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2014 8,883,162'Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors'2014 8,883,160'Dock-and-lock (DNL) complexes for therapeutic and diagnostic use'2014 8,877,202'Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer'2014 8,871,216'Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2014 8,865,176'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2014 8,846,002'Anti-CD74 immunoconjugates and methods of use'2014 8,834,886'Camptothecin-binding moiety conjugates'2014 8,821,868'Anti-pancreatic cancer antibodies'2014 8,808,665'In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents'2014 8,795,662'Anti-mucin antibodies for early detection and treatment of pancreatic cancer'2014 8,778,342'Antibody therapy'2014 8,771,690'Class I anti-CEA antibodies and uses thereof'2014 8,771,987'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2014 8,758,752'RS7 antibodies'2014 8,758,726'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2014 8,759,496'Immunoconjugates with an intracellularly-cleavable linkage'2014 8,753,184'System and method for interactive gameplay with song lyric database'2014 8,741,300'Immunoconjugates with an intracellularly-cleavable linkage'2014 8,734,162'Server and application for interactive gameplay'2014 8,722,047'Humanized anti-HLA-DR antibodies'2014 8,709,382'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2014 8,697,080'Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments'2014 8,658,773'Ultrafiltration concentration of allotype selected antibodies for small-volume administration'2014 8,652,484'Delivery system for cytotoxic drugs by bispecific antibody pretargeting'2014 8,632,752'In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents'2014 8,624,001'Anti-CD19 antibodies'2014 8,617,518'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2013 8,617,558'Camptothecin-binding moiety conjugates'2013 8,613,903'Humanized L243 antibodies'2013 8,603,479'Class I anti-CEA antibodies and uses thereof'2013 8,597,659'Tetrameric cytokines with improved biological activity'2013 8,591,892'FTY720 increases CD74 expression and sensitizes cancer cells to anti-CD74 antibody-mediated cell death'2013 8,586,050'Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy'2013 8,574,575'RS7 antibodies'2013 8,574,854'Anti-mucin antibodies for early detection and treatment of pancreatic cancer'2013 8,569,054'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2013 8,568,729'Anthracycline-antibody conjugates for cancer therapy'2013 8,562,988'Strategies for improved cancer vaccines'2013 8,551,480'Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity'2013 8,545,809'Methods and compositions for improved 18F labeling of proteins, peptides and other molecules'2013 8,535,676'Antibody therapy'2013 8,496,912'In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents'2013 8,491,896'Anti-pancreatic cancer antibodies'2013 8,491,914'Dock-and-lock (DNL) complexes for delivery of interference RNA'2013 8,486,395'Anti-CD19 antibodies'2013 8,481,041'Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy'2013 8,481,003'Anti-CD74 immunoconjugates and methods'2013 8,475,794'Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases'2013 8,470,994'Class I anti-CEA antibodies and uses thereof'2013 8,444,956'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2013 8,435,539'Delivery system for cytotoxic drugs by bispecific antibody pretargeting'2013 8,435,540'Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO'2013 8,435,529'Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy'2013 8,420,783'Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases'2013 8,420,786'Bispecific antibody targeting a complement factor or complement regulatory protein'2013 8,420,086'Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases'2013 8,398,956'In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents'2013 8,383,081'Anti-CD74 immunoconjugates and methods of use'2013 8,372,603'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2013 8,367,037'Anti-CD74 immunoconjugates and methods of use'2013 8,361,464'Anthracycline-Antibody Conjugates for Cancer Therapy'2013 8,349,332'Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2013 8,343,496'Anti-CD74 immunoconjugates and methods'2013 8,343,460'Methods and compositions for F-18 labeling of proteins, peptides and molecules'2013 8,338,140'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'2012 8,337,840'Anti-CD19 antibodies'2012 8,333,971'Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments'2012 8,287,865'Class I anti-CEA antibodies and uses thereof'2012 8,287,864'Structural variants of antibodies for improved therapeutic characteristics'2012 8,282,934'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology'2012 8,277,817'PEGylation by the dock and lock (DNL) technique'2012 8,268,317'Camptothecin-binding moiety conjugates'2012 8,268,312'Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof'2012 8,246,960'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2012 8,216,572'Antibody therapy'2012 8,211,440'Multivalent immunoglobulin-based bioactive assemblies'2012 8,202,509'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2012 8,192,739'Fusion proteins containing recombinant cytotoxic RNAses'2012 8,163,291'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2012 8,158,573'Therapeutic and diagnostic conjugates for use with multispecific antibodies'2012 8,158,129'Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo'2012 8,153,100'Methods and compositions for F-18 labeling of proteins, peptides and other molecules'2012 8,153,433'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2012 8,153,101'Methods and compositions for F-18 labeling of proteins, peptides and other molecules'2012 8,147,831'Anti-CD19 antibodies'2012 8,147,800'Methods and compositions for F-18 labeling of proteins, peptides and other molecules'2012 8,147,799'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2012 8,119,101'Anti-CD74 immunoconjugates and methods of use'2012 8,105,596'Immunotherapy of B-cell malignancies using anti-CD22 antibodies'2012 8,097,252'Methods and compositions for administering therapeutic and diagnostic agents'2012 8,084,029'Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof'2011 8,084,583'RS7 antibodies'2011 8,080,250'Immunoconjugates with an intracellularly-cleavable linkage'2011 8,076,140'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2011 8,067,006'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'2011 8,062,636'Antibody therapy'2011 8,057,793'Anti-CD20 antibodies and fusion proteins thereof and methods of use'2011 8,038,983'Fluorinated carbohydrate conjugates'2011 8,034,352'Tetrameric cytokines with improved biological activity'2011 8,017,736'Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof'2011 8,003,111'Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo'2011 7,999,083'Immunoconjugates with an intracellularly-cleavable linkage'2011 7,993,626'Methods and compositions for F-18 labeling of proteins, peptides and other molecules'2011 7,981,398'PEGylation by the dock and lock (DNL) technique'2011 7,951,369'Chimeric, human and humanized anti-granulocyte antibodies and methods of use'2011 7,939,073'Immunotherapy of B-cell malignancies using anti-CD22 antibodies'2011 7,931,903'Internalizing anti-CD74 antibodies and methods of use'2011 7,932,212'Inhibition of placenta growth factor (PlGF) mediated metastasis and/or angiogenesis'2011 7,931,890'Targeted combination immunotherapy of cancer and infectious diseases'2011 7,919,273'Structural variants of antibodies for improved therapeutic characteristics'2011 7,919,090'Antibody therapy'2011 7,919,087'Internalizing anti-CD74 antibodies and methods of use'2011 7,914,787'Production and use of novel peptide-based agents with bispecific antibodies'2011 7,910,103'Immunotherapy of B-cell malignancies using anti-CD22 antibodies'2011 7,906,118'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology'2011 7,906,121'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2011 7,902,338'Anti-CD19 antibodies'2011 7,901,680'Dock-and-lock (DNL) vaccines for cancer therapy'2011 7,892,547'Methods and compositions for administering therapeutic and diagnostic agents'2011 7,871,622'Stably tethered structures of defined compositions with multiple functions or binding specificities'2011 7,858,070'Multivalent immunoglobulin-based bioactive assemblies'2010 7,837,995'Immunotherapy of B-cell malignancies using anti-CD22 antibodies'2010 7,829,064'Anti-CD74 immunoconjugates and methods'2010 7,820,164'Chimeric, human and humanized anti-CSAP monoclonal antibodies'2010 7,811,570'Method of affecting a function of or ablating a non-malignant cell'2010 7,803,372'Antibody therapy'2010 7,785,880'Mammalian cell lines for increasing longevity and protein yield from cell culture'2010 7,776,311'D-amino acid peptides'2010 7,772,373'Internalizing anti-CD74 antibodies and methods of use'2010 7,683,044'Sphingomyelin therapy of autoimmune disease'2010 7,670,804'Chimeric, human and humanized anti-CSAP monoclonal antibodies'2010 7,666,400'PEGylation by the dock and lock (DNL) technique'2010 7,662,378'Antibody therapy'2010 7,641,891'Chimeric, human and humanized anti-CSAp monoclonal antibodies'2010 7,642,239'Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis'2010 7,641,901'Immunotherapy of autoimmune disorders using antibodies which target B-cells'2010 7,612,180'Humanized L243 antibodies'2009 7,608,425'Methods for protein expression in mammalian cells in serum-free medium'2009 7,597,876'Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules'2009 7,591,994'Camptothecin-binding moiety conjugates'2009

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1994–2021Patents assigned to IMMUNOMEDICS INC (286)· patent assignee history

1994–2002Based in Short Hills, NJ, US· patent location history

1997–2021Based in Mendham, NJ, US· patent location history

2009–2020Patents assigned to IBC PHARMACEUTICALS INC (70)· patent assignee history

2011–2017Patents assigned to GOLDENBERG DAVID M (78)· patent assignee history

2011–2017Patents assigned to CHANG CHIEN-HSING (36)· patent assignee history

2011–2017Patents assigned to HANSEN HANS J (28)· patent assignee history

2014Based in San Francisco, CA, US· patent location history

2016Based in Mendenham, NJ, US· patent location history

2018–2021Based in Delray Beach, FL, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
IMMUNOMEDICS INC	286	1994–2021
GOLDENBERG DAVID Mself	78	2011–2017
IBC PHARMACEUTICALS INC	70	2009–2020
CHANG CHIEN-HSING	36	2011–2017
HANSEN HANS J	28	2011–2017

Locations

Location	Patents	Span
Mendham, New Jersey, US	345	1997–2021
Short Hills, New Jersey, US	12	1994–2002
Delray Beach, Florida, US	6	2018–2021
San Francisco, California, US	2	2014
Mendenham, New Jersey, US	1	2016